Sökresultat
A mobile-based system can assess Parkinsonâs disease symptoms from home environments of patients
…the central nervous system that is associated with a number of motor and non-motor symptoms. The major motor symptoms of the disease include bradykinesia (slowness of initiating voluntary movements), rigidity (increased muscle tone), tremor (a 3–5 Hz tremor at rest) and impaired postural stability. A challenge for the clinical management of the disease is the large within- and between- patient variability in symptom profiles. Furthermore, PD pati…
AlzeCure presenterar ny forskning om smÀrtprojekt pÄ IASP 2024
…024 World Congress on Pain on August 5-9, is now available in its entirety on the company’s website. The poster presentation, which is given by Dr. Märta Segerdahl, Chief Medical Officer at AlzeCure, describes the development of ACD137, the lead drug candidate in the TrkA-NAM program, which exhibits very good potency and selectivity for the target mechanism. The substance has shown powerful pain-relieving effects in several different preclinical m…
Pearls and Pitfalls in Migraine Management
…allela, (Assistant Professor, Neurology specialist at Helsinki University Central Hospital and Helsinki Headache Center), Finland. Mattias Linde, (Professor of Neurology in the Department of Neuroscience, Norwegian University of Science and Technology, Trondheim, and Consultant Neurologist at the Sahlgrenska University Hospital, Gothenburg), Sweden. Anne Christine Poole, (General practitioner and headache specialist at Oslo Headache Clinic), Norwa…
Siponimod EU-godkÀnt för vuxna patienter med sekundÀr progressiv multipel skleros (SPMS) med aktiv sjukdom
…nalmssociety.org/NationalMSSociety/media/MSNationalFiles/Brochures/Brochure-The-MS-Disease-Modifying-Medications.pdf. Accessed January 2020. 2. Kappos L, Cree B, Fox R, et al. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomized, phase 3 study. Lancet. Published online March 22, 2018. http://dx.doi.org/10.1016/S0140-6736(18)30475-6. 3. Mayzent® (siponimod) Summary of Product Characteristics. Nov…
Ultomiris visar bibehÄllen effekt pÄ myastenia gravis efter 60 veckors behandling
…att blockera C5. New, prolonged follow-up results from the Phase III CHAMPION-MG trial open-label extension (OLE) showed that Ultomiris (ravulizumab-cwvz) demonstrated long-term efficacy in adults with anti-acetylcholine receptor (AChR) antibody-positive generalised myasthenia gravis (gMG), with improvements in activities of daily living, muscle strength and quality of life, sustained through 60 weeks.1 Ultomiris was also well tolerated throughout…